Neuland Laboratories News, Corporate filings and Earnings/Conference Calls

Pharmaceuticals company Neuland Laboratories announced Q1FY26 results Total Income: Rs 300.6 crore compared to Rs 444.4 crore during Q1FY25, change -32.40%. EBITDA: Rs 42.1 crore compared to Rs 128.6 crore during Q1FY25, change -67.30%. EBITDA Margin: 14.00% for Q1FY26. PBT: Rs 17.4 crore compared to Rs 130.3 crore during Q1FY25, change -86.80%. PAT: Rs 13.7 crore compared to Rs 98.3 crore during Q1FY25, change -86.10%. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer, said: “While Q1FY26 has been below par as a result of the flow of customer orders, it doesn’t change our outlook on the healthy growth that we anticipate this financial year. The investments we have announced are proceeding according to plan and would be drivers of short as well as long term growth. We continue to focus on cost optimization opportunities across products and processes which will enable us to further strengthen our position in key products.” Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “We see substantial growth this year from our commercial molecules even as there is a significant influx of new business from existing and new customers along with customers’ pipeline projects making exciting progress. Given customers’ interest and evolving expectations we are continuing to invest in our people and capabilities which should see Neuland further differentiated as a CDMO with deep expertise as well as an agile innovative partner.” Result PDF

49.53% Gain from 52W Low

Neuland Laboratories News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Neuland Laboratories from all sources in a single place.